HRPC(SH:600829) Sou Hu Cai Jing·2025-12-02 08:51Core Viewpoint - The stock of Renmin Tongtai reached a limit-up on December 2, closing at 13.49 yuan per share, with a trading volume of 583 million yuan and a total market capitalization of 7.823 billion yuan [1]. Group 1: Company Overview - Renmin Tongtai is the largest pharmaceutical distribution company in Heilongjiang Province, operating in four main sectors: wholesale, retail, logistics, and medical services. The company has a strong regional competitive advantage with extensive coverage of hospitals, grassroots medical institutions, and retail pharmacies [2]. - The retail segment leverages membership and DTP pharmacies to capture prescription outflow, enhancing its market position [2]. Group 2: Product Information - The company's product, Azithromycin dispersible tablets, is indicated for upper respiratory tract infections caused by sensitive bacteria [2]. Group 3: Shareholder Actions and Financial Performance - The controlling shareholder, Harbin Pharmaceutical Group, plans to reduce its stake by no more than 1% of the total share capital. The company does not have an actual controller [3]. - For the period from January to September 2025, Renmin Tongtai reported revenue of 7.846 billion yuan, reflecting a year-on-year increase of 2.19%. However, the net profit attributable to shareholders was 112 million yuan, a decrease of 45.69% year-on-year [3].